GlassScriptPhysician profile
Teri Constance Jumpa
NPI 1205831492
$1,881.36
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $848 · 2022: $689 · 2023: $230 · 2024: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $344.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $188.07 | 2021-2024 | |
| Novo Nordisk INC | $165.27 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Teva Pharmaceuticals USA, INC. | $127.79 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $111.51 | 2021 | |
| Emd Serono, INC. | $109.40 | 2022-2023 | Mavenclad |
| Avion Pharmaceuticals | $73.38 | 2022-2023 | Dhivy |
| Lilly USA, LLC | $71.35 | 2022-2023 | Reyvow, Emgality, Mounjaro |
| Mylan Specialty L.P. | $70.20 | 2021-2023 | Yupelri |
| Alexion Pharmaceuticals, INC. | $68.50 | 2021-2022 | |
| Glaxosmithkline, LLC. | $68.32 | 2021-2022 | |
| Amgen INC. | $63.23 | 2021-2022 | |
| Ucb, INC. | $63.11 | 2021-2022 | |
| Abbott Laboratories | $61.92 | 2021-2024 | Proclaim, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $60.79 | 2022-2023 | Farxiga |
| Supernus Pharmaceuticals, INC. | $55.37 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Banner Life Sciences, LLC | $54.77 | 2023-2024 | |
| Genentech USA, INC. | $53.46 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $51.93 | 2022 | |
| Sk Life Science, INC. | $41.65 | 2022-2023 | |
| Acorda Therapeutics, INC | $40.87 | 2021-2022 | |
| Lundbeck LLC | $39.11 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.21 | 2022 | |
| Biogen, INC. | $21.50 | 2021 | |
| Baxter Healthcare | $19.95 | 2022 | |
| Merck Sharp & Dohme LLC | $19.69 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.65 | 2021 | |
| Almatica Pharma LLC | $18.92 | 2021 | |
| Tanabe Pharma America, INC. | $18.16 | 2021 | |
| Astellas Pharma US INC | $17.05 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $14.61 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $13.82 | 2021 | |
| Neurocrine Biosciences, INC. | $12.93 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.56 | 2021 | |
| Biodelivery Sciences International, INC. | $11.78 | 2021 | |
| Eisai INC. | $11.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Teri Jumpa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.